Aristea S Galanopoulou

Jul 31, 2024 | onlinelibrary.wiley.com | Aristea S Galanopoulou

On September 1, 2024, I will be completing my 8-year term as Editor-in-Chief of Epilepsia Open and will be handing over its leadership to the new Editor-in-Chief Merab Kokaia.

May 23, 2024 | onlinelibrary.wiley.com | Aristea S Galanopoulou

1 TELL US ABOUT YOURSELF I started my academic career in Medicine, studying in Halle/Saale and in Berlin in Germany. At Charité—Universitätsmedizin Berlin, I began working in the field of pediatrics and I encountered neurological diseases for the first time professionally. During my studies, which I finished in 2019, I started my doctoral research focusing on quantifying myelination in children using T1-mapping in magnetic resonance imaging.

May 13, 2024 | onlinelibrary.wiley.com | Aristea S Galanopoulou |Albert Einstein College

1 TELL US ABOUT YOURSELF I grew up in a rural town in Wisconsin and attended the University of Wisconsin for my undergraduate degree in Pharmacology & Toxicology. I received my PhD in Pharmacology from Vanderbilt University investigating pharmacological and genetic treatments for drug-resistant epilepsies. I then moved to Northwestern University to undertake a postdoctoral fellowship in pharmacogenomics.

Nov 3, 2023 | onlinelibrary.wiley.com | Aristea S Galanopoulou

We are excited to welcome and introduce the inaugural lived experience editor and editorial interns among our editorial board. Being a fully open-access journal, we believe that improving the way we communicate the advances or epilepsy research and care to the public is vital for conveying a transparent and accurate message to the community.

Sep 7, 2023 | onlinelibrary.wiley.com | Stéphane Auvin |Aristea S Galanopoulou |Solomon L Moshé |EpiCare ERN Member

CONFLICT OF INTEREST STATEMENT S. Auvin is Deputy Editor for Epilepsia. He has served as consultant or given lectures for Angelini, Biocodex, Eisai, Encoded, Grintherapeutics, Jazz Pharmaceuticals, Neuraxpharm, Orion, Nutricia, Proveca, UCB Pharma, Vitaflo, Xenon, and Zogenix. He has been investigator for clinical trials for Eisai, Jazz Pharmaceuticals, Marinus, Proveca, Takeda, UCB Pharma, and Zogenix.